
Alzamend Neuro (ALZN) Stock Forecast & Price Target
Alzamend Neuro (ALZN) Analyst Ratings
Bulls say
Alzamend Neuro Inc. has demonstrated promising developments in its clinical pipeline, notably with positive top-line results reported in June 2023, which enhance the potential for its therapeutic candidates targeting neurodegenerative diseases and psychiatric disorders. The company's innovative approach, utilizing patented technologies for lithium delivery and immunological restoration, positions it uniquely in the biopharmaceutical market, addressing critical unmet needs in Alzheimer's treatment. Furthermore, the company's current valuation is deemed attractive, suggesting that achieving upcoming milestones and positive trial data could serve as significant catalysts for future stock performance.
Bears say
Alzamend Neuro Inc reported a net loss of $2.7 million, translating to an earnings per share (EPS) of $(1.28), which significantly exceeded the analysts' estimates of $(0.69). The company faces substantial risks including liquidity issues, the potential failure of its drug candidates to show safety and efficacy in trials, and challenges in gaining regulatory approvals, all of which could impede its business prospects. Additionally, external factors such as competition and shifting investor sentiment towards biotech stocks further contribute to concerns regarding the company's future performance.
This aggregate rating is based on analysts' research of Alzamend Neuro and is not a guaranteed prediction by Public.com or investment advice.
Alzamend Neuro (ALZN) Analyst Forecast & Price Prediction
Start investing in Alzamend Neuro (ALZN)
Order type
Buy in
Order amount
Est. shares
0 shares